Skip to main content
. Author manuscript; available in PMC: 2013 Mar 7.
Published in final edited form as: Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):367–372. doi: 10.1016/j.clml.2011.06.005

Table 1.

CD39 Expression (Standard Deviation) As Percentage Expression on Total T Lymphocytes and T-Lymphocyte Subsets

Variable Controls All Patients Stage 0 Stage 1–2 Stage 3–4
T Lymphocytes 5.7 (4.1) 21.9a (14.9) 11.2 (5.6) 21.3b (15.0) 31.1b (14.8)
CD4+ 7.5 (3.5) 23.7a (19.3) 10.4 (8.9) 18.3 (14.8) 40.1b (21.5)
CD8+ 5.0 (5.2) 21.0a (19.6) 13.1 (8.5) 21.1 (20.7) 24.6 (22.6)
a

2P ≤ 0.05 vs. control.

b

2P ≤ 0.05 vs. stage 0.